Progenics Pharmaceuticals, Inc. Initiates Phase 2 Clinical Trials for PRO 140, a Novel HIV Antibody Therapy

TARRYTOWN, N.Y.--(BUSINESS WIRE)--Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the initiation of the phase 2 clinical program for PRO 140, an investigational drug for the treatment of human immunodeficiency virus (HIV) infection. Two, phase 2 clinical trials in HIV-infected individuals will investigate multiple dose levels of PRO 140 via intravenous and subcutaneous routes of administration. Intravenous PRO 140 has the potential for infrequent (e.g., monthly) dosing, whereas subcutaneous PRO 140 may enable self-administration as infrequently as every two weeks. The objective of these phase 2 studies is to identify an optimal dosing regimen of PRO 140 for evaluation in pivotal clinical trials as well as to further assess the investigational drug’s safety and tolerability.

MORE ON THIS TOPIC